A CEO’s Perspective: Building Trust and Credibility Through Stakeholder Engagement

Session details:

In this session, Epicrispr CEO Amber Salzman will discuss the importance of early and consistent engagement with patients, clinicians, scientists, regulators, investors, and other stakeholders in setting up a drug development program for success. Drawing on Epicrispr’s experience advancing its FSHD program, she will explore how aligning what, how, and when you communicate can drive trust, manage expectations, and reinforce differentiation.